Furthermore in allogeneic T cell-depleted bone marrow transplants it has been reported that CD34+ cell dose was the only variable significantly associated with treatment-related mortality, primarily due to infections and cytopenia and therefore higher CD34+ cell doses may improve outcome in engrafting [35]. The gene discussed is CD34; the disease is infection.